A 12-month, Open-label, Multicenter, Phase 4 Study to Evaluate the Efficacy and Safety of OZURDEX Implant 700 µg (Dexamethasone) on Patients With Macular Edema Secondary to Retinal Vein Occlusion in China (YANGTZE Study)
Latest Information Update: 02 Mar 2022
At a glance
- Drugs Dexamethasone (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms YANGTZE
- Sponsors AbbVie; Allergan
Most Recent Events
- 01 Feb 2022 Status changed from active, no longer recruiting to completed.
- 15 Jul 2021 Planned number of patients changed from 70 to 150.
- 13 Oct 2020 Planned number of patients changed from 150 to 70.